The Effect of Semaglutide Compared to Metformin in Obese Women With Polycystic Ovary Syndrome (PCOS): a Randomised Controlled Study (Semaglutide-PCOS Trial).

The goal of this clinical trial is to compare the effect of Semaglutide and metformin on weight loss in obese women with Polycystic Ovarian Syndrome (PCOS) over a 28-week treatment period.
The main question it aims to answer is:
• Which of the 2 drugs, metformin or Semaglutide causes more weight loss when used over a 28 week treatment period in obese women with PCOS?
Participants will be divided into 2 groups by chance. In the first group, participants will be asked to take metformin orally. In the second group, participants will take Semaglutide by injection under the skin weekly.
The maximum duration of participation for the patients in the trial is 32 weeks.
Researchers will compare the weight reduction, quality of life and individuals' wellbeing between the two groups.

Start Date01 Mar 2025

Sponsor / Collaborator

The University of Hull

NCT06222437 / Not yet recruitingPhase 1IIT

Semaglutide and Polycystic Ovarian Syndrome: an Emerging Treatment Strategy

The purpose of this study is to investigate the effect of semaglutide in women with Polycystic Ovarian Syndrome(PCOS ) and determine potential therapeutic benefits.

Start Date01 Jan 2025

Sponsor / Collaborator

Methodist Health System, Inc.

NCT05714683 / Not yet recruitingNot Applicable

A Multi-centre, Prospective, Open-label, Single-arm, Non-interventional, Regulatory Post Marketing Surveillance (rPMS) Study of Rybelsus® (Oral Semaglutide) to Evaluate Safety and Effectiveness in Patients With Type 2 Diabetes Mellitus in Routine Clinical Practice in Korea

The aim of this study is to assess the safety and effectiveness of Rybelsus initiated according to label in adults with Type 2 Diabetes Mellitus (T2DM) under routine clinical practice conditions. Participants will get Rybelsus as prescribed by study doctor. The study will last for about 26 weeks.

Start Date31 Dec 2024

Sponsor / Collaborator

Novo Nordisk A/S

100 Clinical Results associated with Semaglutide (Novo Nordisk)

100 Translational Medicine associated with Semaglutide (Novo Nordisk)

100 Patents (Medical) associated with Semaglutide (Novo Nordisk)

693

Literatures (Medical) associated with Semaglutide (Novo Nordisk)

01 Apr 2024·The American journal of emergency medicine

GLP-1 agonists: A review for emergency clinicians

Review

Author: Koyfman, Alex ; Long, Brit ; Pelletier, Jessica ; Bridwell, Rachel E

INTRODUCTION:

Glucagon-like peptide 1 (GLP-1) based therapies, including GLP-1 agonists, are currently in use for treatment of diabetes and obesity. However, several complications may occur with their use.

OBJECTIVE:

This narrative review provides a focused evaluation of GLP-1 agonist therapy and associated complications for emergency clinicians.

DISCUSSION:

GLP-1 agonists potentiate insulin release and reduce gastric emptying and food intake. These agents have demonstrated significant improvements in glucose control in diabetics and weight loss in obese patients. The two most common agents include subcutaneous semaglutide (Ozempic, approved for type 2 diabetes, and Wegovy, approved for weight loss) and liraglutide (Saxenda, approved for weight loss, and Victoza, approved for type 2 diabetes), though an oral formulation of semaglutide is available (Rybelsus). While these drugs are associated with improved long-term outcomes, there are a variety of associated adverse events. The most common include gastrointestinal (GI) adverse events such as nausea, vomiting, diarrhea, and abdominal pain. Pancreatitis and biliary disease may also occur. Hypersensitivity including injection site reactions have been associated with use, with reports of anaphylaxis and other rashes. Renal adverse events are most commonly associated with severe GI losses. Hypoglycemia may occur when these agents are used with sulfonylureas or insulin. There is also an increased risk of diabetic retinopathy. Due to the current shortage and expense of these medications, many patients have attempted to obtain these medications from non-licensed and unregulated agents, which may be associated with increased risk of serious complications.

CONCLUSIONS:

An understanding of the indications for GLP-1 agonist use and associated adverse events can assist emergency clinicians.

01 Feb 2024·Endocrine connections

GLP-1 and PYY for the treatment of obesity: a pilot study on the use of agonists and antagonists in diet-induced rats

Article

Author: Fassnacht, Martin ; Maack, Christoph ; Nickel, Alexander ; Sequeira, Vasco ; Kloock, Simon ; Ziegler, Christian G ; Dischinger, Ulrich ; Kohlhaas, Michael ; Oertel, Marie

Objective:

Combination therapies with gut hormone analogs represent promising treatment strategies for obesity. This pilot study investigates the therapeutic potential of modulators of the glucagon-like peptide 1 (GLP-1) and neuropeptide Y (NPY) system using GLP-1 receptor agonists (semaglutide) and antagonists (exendin 9-39), as well as non-selective and NPY-Y2-receptor selective peptide tyrosine tyrosine (PYY) analogs (PYY3-36/NNC0165-0020 and NNC0165-1273) and an NPY-Y2 receptor antagonist (JNJ31020028).

Methods:

High-fat diet (HFD)-induced obese rats were randomized into following treatment groups: group 1, nonselective PYY analog + semaglutide (n = 4); group 2, non-selective and NPY-Y2 receptor selective PYY analog + semaglutide (n = 2); group 3, GLP-1 receptor antagonist + NPY-Y2 receptor antagonist (n = 3); group 4, semaglutide (n = 5); and group 5, control (n = 5). Animals had free access to HFD and low-fat diet. Food intake, HFD preference and body weight were measured daily.

Results:

A combinatory treatment with a non-selective PYY analog and semaglutide led to a maximum body weight loss of 14.0 ± 4.9% vs 9.9 ± 1.5% with semaglutide alone. Group 2 showed a maximum weight loss of 20.5 ± 2.4%. While HFD preference was decreased in group 2, a strong increase in HFD preference was detected in group 3.

Conclusions:

PYY analogs (especially NPY-Y2 selective receptor agonists) could represent a promising therapeutic approach for obesity in combination with GLP-1 receptor agonists. Additionally, combined GLP-1 and PYY3-36 receptor agonists might have beneficial effects on food preference.

01 Mar 2024·Peptides

Recent advances in peptide-based therapies for obesity and type 2 diabetes

Article

Author: Flatt, Peter R ; Bailey, Clifford J ; Conlon, J Michael

Options for the treatment of type 2 diabetes mellitus (T2DM) and obesity have recently been expanded by the results of several large clinical trials with incretin-based peptide therapies. Most of these studies have been conducted with the glucagon-like peptide-1 (GLP-1) receptor agonist semaglutide, which is available as a once weekly subcutaneous injection and once daily tablet, and the once weekly injected dual agonist tirzepatide, which interacts with receptors for GLP-1 and glucose-dependent insulinotropic polypeptide (GIP). In individuals with T2DM these therapies have achieved reductions of glycated haemoglobin (HbA1c) by > 2% and lowered body weight by > 10%. In some studies, these agents tested in non-diabetic, obese individuals at much higher doses have lowered body weight by > 15%. Emerging evidence suggests these agents can also offer cardio-protective and potentially reno-protective effects. Other incretin-based peptide therapies in early clinical development, notably a triple GLP-1/GIP/glucagon receptor agonist (retatrutide) and a combination of semaglutide with the amylin analogue cagrilintide (CagriSema), have shown strong efficacy. Although incretin therapies can incur adverse gastrointestinal effects these are for most patients mild-to-moderate and transient but result in cessation of treatment in some cases. Thus, the efficacy of new incretin-based peptide therapies is enhancing the opportunity to control body weight and blood glucose and improve the treatment of T2DM and obesity.

1,039

News (Medical) associated with Semaglutide (Novo Nordisk)

14 hours ago

·www.prnewswire.com

Introducing SHOWW, the Only Telemedicine Company in the Industry Offering a FDA-Regulated 503B Pharmacy Compounded Semaglutide

MIAMI, July 1, 2024 /PRNewswire/ -- Companies can tell their prospective customers anything, but a recently launched business prefers guaranteed results. SHOWW is a weight loss telemedicine brand offering compounded semaglutide, which is the active ingredient in medications like Wegovy® and Ozempic®. SHOWW sets itself apart from other similar companies in the industry with its ultra-high quality FDA-Regulated 503B Pharmacy Compounded Semaglutide. Continue Reading SHOWW your best self. Semaglutide is an injectable medication initially prescribed as a diabetes treatment. The United States Food and Drug Administration approved it as a medical treatment for weight loss in 2021, and it has taken the world by storm since then. Recent research from the University of California, Los Angeles, shows semaglutide can be an effective way to help support weight loss by curbing appetite while reducing the risk of cancer, diabetes, and heart disease in overweight people. Weight loss medications featuring semaglutide have been prominent in the medical community in recent years, but not all providers are the same. Many brand-name semaglutide products can cost over $1,200 monthly. At SHOWW, customers enjoy the same level of quality and safety for a quarter of the price. The company uses clear pricing and transparent processes, with no hidden fees or manipulative tactics. Standing Out in the Crowd Telemedicine is an emerging industry, and many people may not know how simple it can be to speak with a doctor, get a prescription, and order recurring medication delivery from the comfort of home. At SHOWW, there are no appointments or wait times, and clients can receive their semaglutide in as little as four days. SHOWW is the only semaglutide provider that employs a team of licensed doctors specializing in weight loss exclusively to prescribe medication and monitor patients' progress. These physicians do not offer any other services outside personalized weight loss solutions. The in-house team ensures clients aren't forced to endure long wait times to receive a prescription and treatment while preventing crossed wires or communication delays. Safe and Reliable Solutions As the usage of semaglutide grows, it becomes increasingly important for consumers to ensure they receive safe, accurate prescription medications. With SHOWW, clients experience premium telemedicine solutions and a reliable, personalized approach to their healthcare. SHOWW's products are manufactured in a $250 million 503B compounding pharmacy. Unlike 503A facilities, every process at SHOWW must be validated. All medications are submitted for testing prior to being released for sale, ensuring every prescription leaving the facility is of consistent quality and meets all regulatory guidelines. This testing allows 503B compounding pharmacies to guarantee they produce the highest-quality products fit for use in doctor's offices, clinics, and hospitals. The popularity of semaglutide as a weight loss medication has been so widespread that many areas have experienced shortages. SHOWW's 503B compounding pharmacy manufactures its products independently, so its productivity isn't dependent on external supply chains, and customers will not experience shortages. Delivering Guaranteed Results The internet is rife with scam companies out to take a customer's money without making a timely delivery of the product as described. SHOWW works to offer clients as much transparency, security, and convenience as possible while reliably delivering high-quality medication. Clients enjoy fast, free shipping at SHOWW. All orders ship within 24 hours through FedEx or a two-day UPS courier, which means customers receive their medication less than four days after ordering it. Unlike many online providers, SHOWW always has semaglutide in stock, and customers never have to worry about inconvenient delays or issues refilling their medication. According to a litany of customer complaints filed with the Better Business Bureau, many telemedicine providers rely on automated customer support. By contrast, SHOWW offers its clients 24/7 assistance via phone, email, SMS, or live chat. The customer's experience and satisfaction are a priority for SHOWW, and it works to ensure clients can always find answers to their questions. The team is entirely based in the United States, and live representatives are available from 9 a.m. to 6 p.m. EDT daily. All inquiries are answered within 24 hours. Medicine-Assisted Weight Management in Four Steps Getting started with SHOWW is a simple process. Start by completing an online application. In five minutes, clients learn whether SHOWW can help support their weight loss goals. If they are a good match, a licensed doctor will review their information and decide whether semaglutide is an appropriate treatment. "Online consultations at SHOWW are typically free," representatives said. "You'll only pay for the prescription if you qualify after your medical consultation." Once a doctor prescribes the medication, the order is passed on to SHOWW's 503B compounding pharmacy partner and delivered in under four days. As treatments continue, patients monitor their progress and measure it against their goals during monthly doctor check-ins. "We aim to ensure every patient understands their treatment and achieves the best results," SHOWW founders said. "Our support team and physicians are available for free, unlimited follow-ups." In addition to semaglutide, SHOWW offers GLP-1 medications like tirzepatide, which is the active ingredient in similar products like Zepbound™ and Mounjaro®. The company's team of qualified weight loss specialists will determine the most appropriate medications for an individual client's treatment goals, which may include additional drugs like metformin. Semaglutide prescription is not guaranteed for every client and is dependent upon physician approval. Semaglutide treatment is generally not recommended for individuals with a history of medullary thyroid cancer, gallbladder disease, pancreatitis, or multiple endocrine neoplasia syndrome type 2. "Your health journey is unique, and so is our approach to your care," SHOWW founders said. "Rest assured, your treatment plan will be as unique as you are." Affordable and Accessible While SHOWW does not currently accept insurance coverage for its services, the products it provides can often be less expensive than many co-payments. Offering free virtual consultations further reduces the costs and makes medication-assisted weight loss affordable and accessible to ideal candidates. With SHOWW, affordable telemedicine weight loss solutions are available to all qualified patients in the United States. Not only do customers reliably receive their semaglutide medication on time, but they can rest assured that refill prescriptions will also arrive on time and they'll never be left in dark due to shortages or backlogs. Welcome to the SHOWW When it comes to online solutions for weight loss, one telemedicine brand prefers to SHOWW rather than tell. Visit the SHOWW website to learn more about the telemedicine brand or to schedule a free weight loss consultation. It takes less than five minutes to complete the initial online application and discover whether semaglutide might be an appropriate treatment option. Current and prospective customers may also contact SHOWW at (888) 413-7469 or email [email protected]. The brand maintains an online presence on Facebook and Instagram for those who wish to contact SHOWW for social media purposes. SOURCE SHOWW LLC

Drug Approval

28 Jun 2024

·www.fiercepharma.com

Fierce Pharma Asia—Daiichi, Merck's FDA rejection; Wegovy's expansion; Takeda CEO's hunt for China deals

The FDA's rejection of Daiichi and Merck's HER3 ADC, Wegovy's approval in China, and Takeda CEO's appetite for more deals with Chinese biotechs made our news this week. The FDA rejected Daiichi Sankyo and Merck's HER3 antibody-drug conjugate. Novo Nordisk's weight loss star Wegovy secured approval in China. After two large licensing deals, Takeda's CEO is open to more partnerships with Chinese biotechs. And more. 1. Daiichi's lung cancer ADC rejected by FDA in blow to first project under Merck partnership Daiichi Sankyo’s Merck-partnered HER3 antibody-drug conjugate, patritumab deruxtecan, was rejected by the FDA because of third-party manufacturing issues. The drug is one of three ADC programs featured as part of a $4 billion upfront deal between the two companies, and it would have been Merck’s first ADC launch. The partners are working with the contractor and the FDA to address the problems. 2. Novo Nordisk wins approval in China for GLP-1 obesity drug Wegovy China has approved Novo Nordisk’s Wegovy as a weight loss treatment for people with a body mass index of at least 30 or between 27 and 30 with one weight-related risk factor. However, the drug will be unlikely to get national reimbursement after China’s medical insurance authority in an April Q&A ruled out the inclusion of any anti-obesity drugs, along with seven other therapeutic categories, in the national insurance scheme. 3. Takeda keeps looking for China biotech partnerships, CEO says (Bloomberg) Since last year, Takeda has signed major deals with Chinese biotechs Hutchmed and Ascentage Pharma. Now, CEO Christophe Weber told Bloomberg the Japanese pharma “should remain very open of potential partnerships with Chinese biotech.” He also said that the draft BIOSECURE Act would have no impact on Takeda as the company’s manufacturing in China is for the Chinese market. 4. Takeda's anti-CD38 antibody on track for phase 3 after boosting platelet count in bleeding disorder Although Takeda has decided to wind down mezagitamab in myasthenia gravis and systemic lupus erythematosus, it’s still advancing the anti-CD38 antibody in primary immune thrombocytopenia. Latest data from 41 patients in a phase 2b trial showed that the drug improved platelet response compared with placebo across all three doses with what Takeda viewed as a favorable safety profile. 5. Sumitomo Pharma's new CEO weighs layoffs in Japan after sharp sales drop, US job cuts: report Sumitomo Pharma’s new CEO Toru Kimura, who just officially took the helm this week, is weighing a restructuring that could be implemented “as soon as this fiscal year,” he told Nikkei Asia. The reorg would follow a recent layoff round affecting 400 U.S. staffers. Recent revenue declines give the company “no choice but to take further measures, including offering early retirement,” he told the publication. 6. Despite J&J's Rybrevant full nod, FDA encourages Dizal to file rival lung cancer drug for accelerated approval The FDA has endorsed Dizal Pharma’s plan to file its China-approved sunvozertinib in the U.S. for an accelerated approval in previously treated EGFR exon 20 insertion-mutated non-small cell lung cancer, its CEO said. That’s despite the FDA’s recent full approval for Johnson & Johnson’s bispecific antibody Rybrevant in the same indication. The agency clearly sees the need for alternative or better therapies, Dizal’s CEO explained. 7. SK Bioscience begins 'globalization' push, paying $244M for majority stake in contract manufacturer IDT Biologika SK Bioscience has acquired a 60% stake in Germany’s IDT Biologika for 339 billion South Korean won ($244 million) as part of the company’s global expansion push. IDT ranks among the world’s top 10 firms in vaccine production. The transaction enables SK to expand its footprint geographically as well as in new treatment areas such as anti-cancer viruses and cell and gene therapy, SK said. Other News of Note: 8. FDA slams Dr. Reddy's plants in India with a pair of Form 483s 9. Haleon reels in $633M with sale of ex-US nicotine replacement unit to Dr. Reddy's 10. Fosun Pharma offers $690M to take biotech subsidiary Henlius private (Reuters) 11. GenScript's ProBio arm debuts new gene therapy production plant in NJ 12. Terns' ex-MASH drug cuts fat, not muscle or food intake, in GLP-1 combo in mice 13. Glenmark recalls 114 batches of low potassium drug in the US over potentially deadly hyperkalemia risk

Drug ApprovalClinical ResultPhase 2VaccinePhase 3

28 Jun 2024

·www.echemi.com

Scrutinizing the Pricing of Diabetes Drug Ozempic: A Call for Fairness and Transparency

In a recent and impactful tweet, U.S. Senator Bernie Sanders (I-Vt.) has harshly criticized the pricing strategy of the highly-watched diabetes drug Ozempic and its manufacturer, Novo Nordisk A/S. This event has once again thrust the issue of fairness and transparency in drug pricing into the spotlight. In his Wednesday tweet, Sanders detailed his concerns about the pricing of Ozempic. He pointed out that the drug is priced much higher in the U.S. than in other countries, with American consumers paying billions of dollars annually, a staggering 10-15 times more than what consumers in other nations pay. This massive price difference has left many Americans shocked and outraged, questioning why they must bear such a heavy economic burden for the same medication. "Ozempic is likely to become one of the best-selling drugs in history, yet its manufacturer Novo Nordisk is making massive profits from American consumers through its high-pricing strategy," Sanders wrote in his tweet. "This unfair pricing strategy not only imposes a huge economic burden on American consumers but also exposes the serious problems in the pharmaceutical market." Sanders' criticism of Ozempic's high costs is not the first of its kind. As early as March this year, he had expressed concerns about the "outrageous" price of the drug and considered holding a hearing on the issue. As the chair of the Senate Health, Education, Labor and Pensions (HELP) Committee, Sanders has been dedicated to driving reforms in the healthcare sector to ensure patients have access to high-quality and affordable medical services. After Sanders' strong protest, Novo Nordisk CEO Lars Fruergard Jørgensen finally agreed to testify in the Senate and provide explanations and clarifications on the pricing of Ozempic. Prior to the agreement, there had been a heated public debate over the arrangements for the hearing. Sanders' team accused Novo Nordisk of not cooperating, while the company insisted that it was willing to provide the necessary evidence and information for the hearing. In fact, the high cost of Ozempic is not an isolated case. Similar price discrimination phenomena are common in the pharmaceutical market. Some pharmaceutical companies often set different price standards in different countries and regions to maximize their profits. This practice not only leaves consumers confused and dissatisfied but also exacerbates the global inequality in access to medical resources. Governments and international organizations are strengthening regulations and cooperation to promote fairness and transparency in the pharmaceutical market to address this issue. For example, the World Health Organization (WHO) has repeatedly called on governments to strengthen the regulation and control of drug prices to ensure that patients have access to reasonably priced medications. At the same time, some countries and regions are actively exploring the establishment of drug price negotiation mechanisms to reduce drug prices through collective bargaining. With the push from political figures like Sanders, the issue of fairness and transparency in the pharmaceutical market is expected to receive more widespread attention and solutions in the future. We look forward to a more fair and transparent pharmaceutical market that allows every patient to access high-quality and affordable medical services.

100 Deals associated with Semaglutide (Novo Nordisk)

External Link

KEGG	Wiki	ATC	Drug Bank
D10025	Semaglutide (Novo Nordisk)	A10BJ06	DB13928

R&D Status

Approved

10 top approved records.

to view more data

Indication	Country/Location	Organization	Date
Obesity	US	Novo Nordisk, Inc.	04 Jun 2021
Overweight	US	Novo Nordisk, Inc.	04 Jun 2021
Diabetes Mellitus, Type 2	US	Novo Nordisk, Inc.	05 Dec 2017

Developing

10 top R&D records.

to view more data

Indication	Highest Phase	Country/Location	Organization	Date
Albuminuria	Phase 3	CA	Novo Nordisk A/S	14 Mar 2022
Albuminuria	Phase 3	DE	Novo Nordisk A/S	14 Mar 2022
Albuminuria	Phase 3	NL	Novo Nordisk A/S	14 Mar 2022
Albuminuria	Phase 3	ES	Novo Nordisk A/S	14 Mar 2022
Diabetes Mellitus	Phase 3	CA	Novo Nordisk A/S	14 Mar 2022
Diabetes Mellitus	Phase 3	DE	Novo Nordisk A/S	14 Mar 2022
Diabetes Mellitus	Phase 3	NL	Novo Nordisk A/S	14 Mar 2022
Diabetes Mellitus	Phase 3	ES	Novo Nordisk A/S	14 Mar 2022
Prediabetic State	Phase 3	CA	Novo Nordisk A/S	06 Sep 2021
Prediabetic State	Phase 3	DK	Novo Nordisk A/S	06 Sep 2021

Clinical Result

Indication

Phase

Evaluation

View All Results

Study	Phase	Population	Analyzed Enrollment	Group	Results	Evaluation	Publication Date


NCT03819153 (FLOW, PRNewswire) Manual	Phase 3	Diabetes Mellitus, Type 2 \| Chronic Kidney Diseases	-	Semaglutide 1 mg	zvxfjlyqpr(syslrbuxze) = tpzjlfiuca ecychricvk (oxwosgsecn ) Met View more	Positive	24 Jun 2024
				Placebo	zvxfjlyqpr(syslrbuxze) = gpnfrtwerd ecychricvk (oxwosgsecn ) Met View more
NCT04788511 (STEP-HFpEF, CTgov)	Phase 3	Heart Failure \| Obesity	529	Semaglutide (Semaglutide 2.4 mg)	dcmrnvfdvq(vpiindcdgf) = pcuchhtfzr nswdsobsxx (iwvbxluums, mwyktguqkf - bppuhllkyd) View more	-	11 Jun 2024
				placebo+semaglutide (Placebo)	dcmrnvfdvq(vpiindcdgf) = dhspooducu nswdsobsxx (iwvbxluums, ltqskqbcnk - kgozoapwwa) View more
NCT03987451 (CTgov)	Phase 2	Nonalcoholic Steatohepatitis \| Liver Injury \| Liver Cirrhosis	71	Placebo (semaglutide)	ykkvlshhgb(tfyptnrkuj) = hlnddknrdm vsfickuigk (kerdzmsyqf, ozvwbransf - pewubbmspg) View more	-	29 May 2024
NCT03819153 (FLOW, PRNewswire) Manual	Phase 3	Chronic Kidney Diseases \| Diabetes Mellitus, Type 2	3,533	Semaglutide	ihgnxibkpa(tjhkhtryje) = orujptqruz wsrdupmmqp (byzlbqajda ) View more	Positive	24 May 2024
				Placebo	yahplvpiny(xeirgkoafy) = luykzlzwiv zvcgqtzkxv (adyddughht ) View more
NCT04216589 (CTgov)	Phase 2	Cardiovascular Diseases \| Metabolic Syndrome \| HIV Infections ... View more	51	semaglutide	gtvufeelji(nwvnlbfyou) = amuojkllbk euwvwlbrib (fzvtvfbyth, tbhqkkxytg - weecugjapl) View more	-	17 May 2024
SELECT (Biospace) Manual	Not Applicable	Obesity	-	Wegovy	nivvtnyrwg(fkidayubpd) = tjykwiwrxx akyvgbomhr (solswvgwnq )	Positive	14 May 2024
SELECT (Literature) Manual	Not Applicable	Obesity	-	Semaglutide (not diabetes)	yicarsynci(umvbutmxrt) = pdbxajkecn pamktjrwcc (dkohebskjh ) View more	Positive	13 May 2024
NCT03574597 (SELECT, Pubmed) Manual	Phase 3	Obesity	17,604	Semaglutide	phxaaqlclm(thjhorahmo) = jvdjarjuzm klpwpqqrki (ygbdfxguee ) View more	Positive	13 May 2024
NCT04916470 (Literature) Manual	Phase 3	Diabetes Mellitus, Type 2 \| Heart Failure	616	Semaglutide	dnaeqldxdw(qfddtrulgs) = kpngsvexwv zlkiequrxb (xgptlhodoj ) View more	Positive	06 Apr 2024
				Placebo	dnaeqldxdw(qfddtrulgs) = ouykmbxzxx zlkiequrxb (xgptlhodoj ) View more
NCT04916470 (Pubmed)	Phase 3	Diabetes Mellitus, Type 2 \| Heart Failure	616	Semaglutide	ylmdkaofzz(dghhglgpwg) = taxbwsfygb oddzbrjjsm (ixtbzqixjw ) View more	-	06 Apr 2024
				Placebo	ylmdkaofzz(dghhglgpwg) = sdfbtxtygs oddzbrjjsm (ixtbzqixjw ) View more

Translational Medicine

Boost your research with our translational medicine data.

view full example data

Deal

Boost your decision using our deal data.

view full example data

Core Patent

Boost your research with our Core Patent data.

view full example data

Clinical Trial

Identify the latest clinical trials across global registries.

view full example data

Approval

Accelerate your research with the latest regulatory approval information.

view full example data

Regulation

Understand key drug designations in just a few clicks with Synapse.

view full example data

Get started for free today!

Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.

Start your data trial now!

Synapse data is also accessible to external entities via APIs or data packages. Leverages most recent intelligence information, enabling fullest potential.

Bio

Bio Sequences Search & Analysis

Chemical

Chemical Structures Search & Analysis